… The development of ganciclovir's prodrug, valganciclovir, … of valganciclovir for treatment for
CMV disease we designed an … Children and patients with life-threatening CMV disease were …

… of their disease.5 Retinitis is the most common type of cytomegalovirus disease in patients
with AIDS, accounting for 75% to 85% of all cytomegalovirus disease.2, 3 Cytomegalovirus …

… -CMV drug but must be given parenterally and is completely dependent on renal clearance
for elimination. Prevention of CMV disease … Ganciclovir treatment of cytomegalovirus disease …

… ganciclovir therapy after the initial treatment, and who had adequate follow-up, all 21 had a
recurrence in their cytomegalovirus disease … , Sugar J: Parenterally administered acyclovir for …

… for some human CMV strains. Intravitreal administration of ganciclovir was reported in an
AIDS patient with CMV retinitis who was precluded from parenteral therapy due to significant …

… trial of antiviral treatment for symptomatic congenital CMV disease has been conducted …
The earlier randomized, controlled trial showed a benefit of 6 weeks of parenteral ganciclovir …

… of parenteral ganciclovir plus foscarnet are furthermore effective in controlling CMV retinitis
that previously progressed under ganciclovir … treatment is the combined use of an intraocular …

… and ganciclovir groups in the overall incidence of CMV disease (table I) or when analysed
for specific transplanted organ type after 6 months of treatment; CMV disease … and ganciclovir …

… Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients.
JInfecf-Dis 167:1183-1188,1993. Jacobson, MA, van der Horst, C, Causey, DM, Dehlinger…

… 6 weeks of parenteral therapy. Currently because high dose oral ganciclovir appears to be
… , are becoming available, prolonged treatment seems justified and warrants further studies. …